Biodesix (BDSX) has just wrapped up Q1 2026, with investors looking closely at how the latest headline figures line up with its recent track record of revenue growth and ongoing losses. Over the past six reported quarters, the company has seen revenue move from US$18.2 million in Q3 2024 to US$28.8 million in Q4 2025, while quarterly EPS shifted from a loss of US$1.40 to a loss of US$0.49, and trailing twelve month EPS moved from a loss of US$7.57 in Q3 2024 to a loss of US$4.67 in Q4 2025. That mix of higher sales against persistent losses sets the tone for this earnings release, with investors likely to focus on whether improving unit economics and operating discipline are starting to ease the pressure on margins.

See our full analysis for Biodesix.

With the latest numbers on the table, the next step is to see how they line up against the widely followed growth and risk narratives around Biodesix, and where those stories may need a reset.

Revenue up to US$88.5 million over the last year

• On a trailing twelve month basis, total revenue has moved from US$65.6 million in Q3 2024 to US$88.5 million by Q4 2025, while the trailing net loss has shifted from US$43.8 million to US$35.3 million over the same window.
• Consensus narrative highlights expanding access and digital ordering as key growth drivers, and this revenue and loss profile partly supports that view while also showing the tension that higher sales are still paired with sizeable losses.
  • Revenue of US$88.5 million alongside a trailing EPS loss of US$4.67 suggests that, even with more tests and development services, the cost base remains heavy.
  • The consensus focus on improved gross margins and operational scaling sits next to a trailing net loss of US$35.3 million, which keeps funding and execution risks firmly on the radar.

Losses narrowing but still US$35.3 million over TTM

• Over the six reported quarters, quarterly net loss (excluding extra items) has ranged from US$11.5 million in early 2024 to US$4.0 million in Q4 2025, with trailing twelve month net loss at US$35.3 million in Q4 2025 versus US$43.8 million in Q3 2024.
• Bulls argue that expanding primary care coverage and stronger clinical validation can eventually turn this around, and the shift from larger quarterly losses toward US$4.0 million supports that optimism while still leaving a sizeable gap to profitability.
  • The bullish narrative leans on multiyear revenue growth assumptions and margin expansion, and the move from double digit quarterly losses to a US$4.0 million loss in Q4 2025 is directionally helpful for that view.
  • At the same time, trailing EPS is still a US$4.67 loss, so even bullish assumptions about better margins need to account for how long this level of loss can be supported with less than one year of cash runway highlighted in the risk summary.

Bulls suggest the recent shift toward higher revenue and smaller quarterly losses could mark the early stages of the story they are betting on, and it is worth seeing how that case is built out in detail in the 🐂 Biodesix Bull Case.

Valuation tension between DCF fair value and P/S

• The stock trades at about US$14.94 against a DCF fair value of roughly US$79.84, while the P/S ratio of 1.7x sits above the broader US Healthcare industry at 1.2x but below a 3.4x peer average.
• Bears focus on financial risks such as negative shareholders’ equity, substantial dilution and less than one year of cash runway, and these concerns line up with a company that is unprofitable today despite trading on a higher P/S than the wider industry.
  • Forecast revenue growth of about 14.4% a year, together with an ongoing net loss of US$35.3 million over the last twelve months, leaves plenty of room for skeptics to question whether the large DCF fair value gap is justified.
  • With the share price below both the 30.50 analyst target and the DCF fair value, bears can still point to balance sheet pressure and recent dilution as reasons the market might keep discounting those longer term projections.

Skeptics point out that a wide gap to DCF fair value does not erase balance sheet pressure, and understanding how cautious investors frame that trade off can be helpful before you make up your mind, so it is worth checking the 🐻 Biodesix Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Biodesix on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

The mix of optimism and concern in this story is clear, so consider testing the data yourself and decide what it means for your portfolio by looking at the 3 key rewards and 5 important warning signs.

See What Else Is Out There

Biodesix is still carrying sizeable losses, a heavy cost base and balance sheet pressure, even as revenue and EPS trends move in a more supportive direction.

If you want ideas with fewer financial red flags and potentially steadier foundations, check out 72 resilient stocks with low risk scores so you can compare Biodesix with companies that score better on resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.